Navigation Links
Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division

INDIANAPOLIS, Sept. 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Robert J. Heine, M.D., Ph.D., F.R.C.P., will join Lilly in January, 2008, as Executive Medical Director for the Diabetes and Endocrine division responsible for development of Lilly's expanding diabetes and obesity R&D portfolio. Dr. Heine replaces Dr. Meng Hee Tan, Distinguished Medical Fellow, Diabetes and Endocrine, who will retire at the end of September after 8 years of outstanding service to the company.

"Lilly has a growing and exciting diabetes and obesity R&D portfolio that demands exceptional clinical leadership to guide and successfully develop," said Vince Mihalik, Vice President and Global Brand Development Platform Leader, Diabetes, Obesity and Endocrine. "Robert is widely recognized and respected in the diabetes community for his scientific and clinical excellence and his considerable leadership abilities. He'll be a fantastic addition to the Lilly team."

Heine is currently professor of diabetology in the Department of Endocrinology and director of the Diabetes Centre at the VU (Vrije Universiteit) University Medical Center in Amsterdam, Netherlands. In addition to involvement in several research projects, Heine holds positions within the European Association for the Study of Diabetes (EASD), the European Foundation for the Study of Diabetes (EFSD) and the American Diabetes Association (ADA), including chair of the EASD subcommittee for Clinical Research Training, president of the organizing committee for the 2007 EASD annual meeting, and a member of the ADA Expert Committee on guidelines for the treatment of hyperglycemia in type 2 diabetes. He is a prolific author, with more than 350 published papers, and currently serves as associate editor of Diabetic Medicine and an editorial board member for several other publications. Heine's primary research interests include the epidemiology and pathophysiology of type 2 diabetes.

"We couldn't be more pleased that Dr. Heine has decided to bring his considerable talents to Lilly," said David Moller, M.D., Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories. "Robert's outstanding clinical experience and depth of scientific expertise will be a major contributor to the sustained leadership of Lilly in diabetes and related metabolic disorders as we continue to bring novel medicines to patients in need around the world."

"It's a privilege to join a team with such an impressive history of innovation and one that is also shaping the future of diabetes care," said Heine. "I'm excited for the opportunity to work in a new and dynamic atmosphere at Lilly with a group of truly talented scientists."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at


(Logo: )

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Crohns Patient Robert Hill’s greatest achievemen
2. Relapse in Risk Management System Claims the Life of Robertson
3. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
4. Distinguished Scientist Award Conferred on Manchester Dentist
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Is Diabetes the Leading Cause of Kidney Failure in India
7. Diabetes and Depression often go hand-in-hand
8. Vitamin E, the latest warrior against diabetes
9. Thirty minutes of work up per day reduces the risk of Diabetes
10. New Drug for Diabetes
11. Diabetes, obesity rates shooting up
Post Your Comments:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/28/2015)... ... ... Pixel Film Studios is back again with ProPanel: Pulse . With ... Users have full control over angle of view, speed method, start point, end point, ... get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape masks, all ...
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... recent 2015 American Dental Association meeting in Washington D.C. revolved around the fact that ... patient’s overall health. The talk stressed the link between periodontal disease (more commonly referred ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... changing the way that they are handling security in light of the recent terrorist ... presence in an attempt to stop an attack from reaching U.S. soil. Especially around ...
(Date:11/27/2015)... NC (PRWEB) , ... November 27, 2015 , ... A ... effective ways to treat it. Surviving Mesothelioma has just posted the findings on ... at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
Breaking Medicine Technology: